Limits...
Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures.

Weisenberg JL, Wong M - Neuropsychiatr Dis Treat (2011)

Bottom Line: Ezogabine is predominantly metabolized via glucuronidation.Its half-life is 8 hours, suggesting a need for three-times-a-day administration.Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.

ABSTRACT
Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, emphasizing the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and bipolar disease, but these are based primarily on experimental models.

No MeSH data available.


Related in: MedlinePlus

Chemical structure of ezogabine.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3140293&req=5

f1-ndt-7-409: Chemical structure of ezogabine.

Mentions: Ezogabine is an ethyl N-(2-amino-4-[{4-fluorophenyl}methylamino]phenyl carbamate) (Figure 1). Previously known as D-23129, it is also known by the international nonproprietary name of retigabine in Europe and most of the world, but the adopted name in the United States is ezogabine. This drug was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for adjunctive treatment of partial-onset seizures in adults. It appears to work by a unique mechanism of action compared with other currently available AEDs.


Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures.

Weisenberg JL, Wong M - Neuropsychiatr Dis Treat (2011)

Chemical structure of ezogabine.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3140293&req=5

f1-ndt-7-409: Chemical structure of ezogabine.
Mentions: Ezogabine is an ethyl N-(2-amino-4-[{4-fluorophenyl}methylamino]phenyl carbamate) (Figure 1). Previously known as D-23129, it is also known by the international nonproprietary name of retigabine in Europe and most of the world, but the adopted name in the United States is ezogabine. This drug was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for adjunctive treatment of partial-onset seizures in adults. It appears to work by a unique mechanism of action compared with other currently available AEDs.

Bottom Line: Ezogabine is predominantly metabolized via glucuronidation.Its half-life is 8 hours, suggesting a need for three-times-a-day administration.Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.

ABSTRACT
Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, emphasizing the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and bipolar disease, but these are based primarily on experimental models.

No MeSH data available.


Related in: MedlinePlus